# Phase 1, Multi-Center, Open-Label Study of VT3989 in Patients with Refractory Locally Advanced or Metastatic Solid Tumors Enriched for Tumors Harboring Mutations of the Neurofibromatosis Type 2 Gene (mutant NF2 or mNF2)

**Status:** Recruiting

## Eligibility Criteria

**Sex:** Male or Female
**Age Group:** 18 years and over
This study is NOT accepting healthy volunteers

**Inclusion Criteria:**

- metastatic solid tumor or mesothelioma that has progressed on or after all approved therapies of known clinical benefit - able to walk and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours - see link to clinicaltrials.gov for complete inclusion and exclusion criteria

**Exclusion Criteria:**

- active brain metastases or primary CNS (central nervous system) cancer - HIV positive or active Hepatitis B or Hepatitis C - significant heart disease - another active cancer - women who are pregnant or breast feeding

## Conditions & Interventions

**Conditions:**
Cancer
**Keywords:**
Clinics and Surgery Center (CSC), Mesothelioma, solid tumors

## More Information

**Description:** This study is intended to find the highest amount of the study drug, VT3989, which can be safely taken by patients without causing too many side effects and to determine the recommended dose and dosing schedule for further research, how much of the study drug gets into the blood stream and how long it takes to be cleared, and if the study drug will shrink tumors.
**Study Contact:** Robert Kratzke - kratz003@umn.edu
**Principal Investigator:** Robert Kratzke
**Phase:** PHASE1
**IRB Number:** STUDY00019430